Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary. CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- CVS Health price target lowered to $60 from $67 at Truist
- CVS Health price target lowered to $58 from $66 at Mizuho
- Trump Trade: Federal funding plan endorsed by Trump fails
- CVS Health has strong position in DOJ case, says TD Cowen
- Republicans spending package includes no PBM reform, Punchbowl says
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
